BioPorto Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Tony Pare

Chief executive officer

kr.6.3m

Total compensation

CEO salary percentage	55.7%
CEO tenure	1.5yrs
CEO ownership	n/a
Management average tenure	1.5yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tony Pare's remuneration changed compared to BioPorto's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-kr.75m
Dec 31 2022	kr.6m	kr.4m	-kr.76m
Sep 30 2022	n/a	n/a	-kr.68m
Jun 30 2022	n/a	n/a	-kr.62m
Mar 31 2022	n/a	n/a	-kr.59m
Dec 31 2021	kr.8m	kr.374k	-kr.57m

Compensation vs Market: Tony's total compensation ($USD913.34K) is above average for companies of similar size in the UK market ($USD348.41K).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.

CEO

Tony Pare (59 yo)

1.5yrs

Tenure

kr.6,340,000

Compensation

Mr. Anthony Paul Pare, also known as Tony, serves as Chief Executive Officer of BioPorto A/S since November 2021. He served as Chief Commercial Officer at T2 Biosystems, Inc. since January 08, 2020. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anthony Pare	Chief Executive Officer	1.5yrs	kr.6.34m	no data
Neil Goldman	Executive VP & CFO	1.5yrs	kr.5.23m	no data
Lars Uttenthal	Chief Scientific Officer	no data	no data	no data
Gry Larsen	General Counsel	no data	no data	no data
Jennifer Zonderman	VP of Global Marketing & US Commercialization	4yrs	no data	no data
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	less than a year	no data	no data

1.5yrs

Average Tenure

Experienced Management: BIOPOC's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Donnie Hardison	Independent Vice Chairman of the Board	2.1yrs	kr.715.00k	no data
John McDonough	Independent Chairman of the Board	2.1yrs	kr.835.00k	no data
Claudio Ronco	Member of Scientific Advisory Board	9.3yrs	no data	no data
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	9.3yrs	no data	no data
Ninfa Saunders	Director	less than a year	no data	no data
Michael Singer	Independent Director	3.8yrs	kr.715.00k	0.062% DKK 328.6k
Peter Eriksen	Director	1.5yrs	kr.292.00k	0.039% DKK 207.0k
Jan Christensen	Independent Director	2.1yrs	kr.275.00k	no data
Andrew Lewington	Vice Chairman of Scientific Advisory Board	9.3yrs	no data	no data
Laurent Jacob	Member of Scientific Advisory Board	9.3yrs	no data	no data
Michael Haase	Member of Scientific Advisory Board	9.3yrs	no data	no data
Hilde Geus	Member of Scientific Advisory Board	9.3yrs	no data	no data

6.5yrs

Average Tenure

62yo

Average Age

Experienced Board: BIOPOC's board of directors are considered experienced (6.5 years average tenure).

BioPorto Management

Management criteria checks 2/4

Key information

Recent management updates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Recent updates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report First Half, 2024 Results on Aug 01, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

BioPorto A/S Maintains Earnings Guidance for the Year 2023

BioPorto A/S Maintains Financial Guidance for 2023

Less than half of directors are independent

BioPorto A/S, Annual General Meeting, Apr 27, 2023

Less than half of directors are independent

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age